CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 20 mg orally once daily for one monthAI-extracted
Key inclusion· 5
  • Age 18 years or older
  • Previously taken one or more statins
  • Withdrawn from statins due to perceived side effects
  • Side effects developed within 2 weeks of statin initiation
Key exclusion· 9
  • History of neuropathy
  • Regularly taking prescribed analgesia
  • History of chronic pain condition
  • History of severe mental illness

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02668016
NCT02668016Phase 4Completed

Self-Assessment Method for Statin Side-effects Or Nocebo

Imperial College London·interventional·Posted Jan 29, 2016·Updated Aug 7, 2024

In Brief

A Phase 4 clinical trial evaluating Atorvastatin and Placebo for Adverse Effects and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Front-line clinicians cannot currently test for an individual participant whether symptoms experienced are the pharmacological result of a statin or due to other phenomena. In this trial, participants who have previously ceased statins due to side effects will be offered the opportunity to undergo twelve randomly ordered 1-month periods. There will be four periods of no medication, four periods of placebo and four periods of statin. The placebo and the statin pills will be identical in appearance. Participants will record on a daily basis side-effects experienced. At the end of the study, the one-month sessions are sorted into the order shown above. The participant can then observe directly how much of the increase in symptoms seen with statin is also seen with placebo. 1. Hypothesis 1: that \>30% of participants enrolling for the study will complete it. 2. Hypothesis 2: Overall \>50% of symptom burden is nocebo rather than pharmacological 3. The investigators will define the Nocebo proportion of side effects. 4. Hypothesis 3: that the majority of participants, at 6 months after completion, will either be taking statins or have declined statins for reasons other than perceived side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 29, 2016
Enrollment StartMar 1, 2016
Primary CompletionOct 31, 2020
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.4 years ago

Interventions

Atorvastatindrug

Atorvastatin 20mg tablets taken orally once daily for one month.

Placeboother

Placebo tablets taken orally once daily for one month